Cartalax (Bioregulator)

Research Overview

Cartalax serves as a research tool for investigating cartilage-specific bioregulation and chondral tissue function in laboratory settings. This synthetic peptide bioregulator belongs to the class of Khavinson short peptides originally developed through research on tissue-specific regulatory mechanisms. Musculoskeletal tissue research also investigates BPC-157 for connective tissue repair through growth factor pathways and TB-500 for actin-mediated tissue regeneration. The bioregulator concept proposes that short peptide sequences associated with specific tissues can act as information molecules that influence cellular function in corresponding target tissues.

Cartalax research applications extend across multiple areas of musculoskeletal biology including chondrocyte function, cartilage matrix composition, joint tissue homeostasis, cartilage-bone interactions, and musculoskeletal aging processes. Laboratory protocols examine these effects in cell culture systems, cartilage explants, and preclinical animal models to understand cartilage tissue regulation at molecular and cellular levels.

The peptide’s defined cartilage-associated sequence provides research interest in tissue selectivity and targeted cellular regulation. Studies investigate how this short peptide interacts with chondrocytes, the mechanisms underlying tissue-specific effects, and potential applications in understanding joint function and musculoskeletal system biology. Research models include primary chondrocyte cultures, cartilage explant systems, and various joint tissue assessment protocols.

Molecular Characteristics

Defined Composition:

• Classification: Synthetic peptide bioregulator (Khavinson short peptide)
• Source/Origin: Synthetic (solid-phase peptide synthesis)
• Amino Acid Sequence: Ala-Glu-Asp (AED)
• Molecular Formula: C₁₂H₁₉N₃O₈
• Molecular Weight: 333.29 Da
• Form: White to off-white lyophilized powder
• Solubility: Water, phosphate buffered saline, cell culture media

Cartalax is a single, defined molecular entity: the synthetic tripeptide Ala-Glu-Asp (AED). Rather than a complex preparation, it is a chemically synthesized short peptide with a precise sequence and molecular weight, produced by solid-phase peptide synthesis. This defined composition supports reproducible characterization and consistent biological activity profiles across research models.

As a Khavinson-class short peptide, the AED tripeptide is theorized to serve as an information molecule, carrying tissue-specific regulatory signals that influence gene expression and cellular function in cartilage target tissues. Its low molecular weight (333.29 Da) is consistent with the short regulatory peptides studied for direct interaction with cellular regulatory mechanisms.

Bioregulator Peptide Research Background

Cartalax belongs to the research category of cytomaxes (bioregulator peptides) developed to investigate tissue-specific cellular regulation. This research approach emerged from studies on how short peptide signals influence cellular differentiation, function, and tissue homeostasis. The bioregulator hypothesis proposes that:

1. Tissues are associated with specific peptide signals that regulate cellular function
2. Short peptide sequences linked to specific tissues demonstrate selective affinity for corresponding tissues
3. These peptides may influence gene expression and protein synthesis in target cells
4. Bioregulator effects occur through interaction with cellular regulatory mechanisms

Research on cartilage bioregulators like Cartalax investigates these mechanisms in musculoskeletal tissue contexts, examining how the AED peptide signal might modulate chondrocyte function, matrix production processes, and joint tissue homeostasis in experimental models.

Research Applications

Chondrocyte Function Research

Cartalax serves as a research tool for investigating cartilage cell function and regulation:

• Cell Viability and Proliferation: Investigation of chondrocyte survival, proliferation rates, and cellular turnover in culture systems
• Gene Expression Studies: Research on cartilage-specific gene expression including collagen types (Col2A1, Col9A1), aggrecan, and matrix proteins
• Protein Synthesis Regulation: Examination of extracellular matrix component production and secretion
• Differentiation Maintenance: Studies on chondrocyte phenotype stability and dedifferentiation resistance
• Metabolic Activity Research: Investigation of chondrocyte metabolic pathways and energy production

Laboratory protocols employ primary chondrocyte cultures (articular, growth plate), immortalized chondrocyte cell lines (C28/I2, T/C-28a2), and 3D culture systems to characterize Cartalax effects on cartilage cell function.

Extracellular Matrix Research

Research applications extend to cartilage matrix composition and regulation:

• Collagen Synthesis Studies: Investigation of type II collagen production, fibril formation, and organization
• Proteoglycan Research: Examination of aggrecan synthesis, glycosaminoglycan chain composition, and aggregation
• Matrix Assembly Investigation: Studies on extracellular matrix organization and supramolecular structure
• Matrix Degradation Research: Analysis of matrix metalloproteinase (MMP) expression and activity regulation
• ADAMTS Enzyme Studies: Investigation of aggrecanase expression and proteoglycan cleavage mechanisms

Experimental approaches include biochemical assays for matrix components, immunohistochemistry, gene expression analysis, and enzyme activity measurements to understand matrix regulation.

Cartilage Tissue Homeostasis Studies

Laboratory studies investigate Cartalax in cartilage maintenance and homeostasis contexts:

• Anabolic-Catabolic Balance: Research on equilibrium between matrix synthesis and degradation
• Inflammatory Mediator Research: Examination of cytokine effects on chondrocytes (IL-1β, TNF-α, IL-6)
• Oxidative Stress Response: Studies on reactive oxygen species effects and antioxidant systems in cartilage
• Growth Factor Signaling: Investigation of TGF-β, IGF-1, and BMP signaling in chondrocyte regulation
• Mechanical Loading Response: Research on mechanotransduction and load-induced gene expression

Research protocols examine how bioregulator peptides might influence the balance between anabolic and catabolic processes in cartilage tissue models.

Joint Tissue Aging Research

Cartalax serves as a tool for investigating age-related changes in cartilage:

• Cellular Senescence Studies: Examination of aging markers in chondrocytes and joint tissues
• Telomere Research: Investigation of telomere dynamics in cartilage cells
• Age-Related Matrix Changes: Studies on collagen cross-linking, proteoglycan content, and water composition
• Chondrocyte Function Decline: Research on reduced synthetic capacity and responsiveness with aging
• Oxidative Damage Accumulation: Analysis of advanced glycation end-products (AGEs) and oxidative modifications

Research protocols employ aging models, senescence-associated marker analysis, and comparative studies across different age groups in experimental systems.

Cartilage-Bone Interface Research

Laboratory studies examine Cartalax effects on osteochondral interactions:

• Subchondral Bone Research: Investigation of cartilage-bone communication and reciprocal regulation
• Calcified Cartilage Studies: Examination of the tidemark and calcified cartilage layer function
• Bone-Cartilage Signaling: Research on molecular signals crossing the osteochondral junction
• Endochondral Ossification: Investigation of cartilage template and bone formation processes
• Joint Biomechanics: Studies on load distribution and mechanical properties across cartilage-bone interface

Research approaches include osteochondral explant cultures, co-culture models, and biomechanical testing of cartilage-bone constructs.

Cartilage Tissue Engineering Research

Cartalax research applications include cartilage regeneration and tissue engineering:

• Scaffold-Based Studies: Investigation of chondrocyte function in 3D biomaterial scaffolds
• Cell-Scaffold Interactions: Research on cell adhesion, migration, and matrix deposition in engineered constructs
• Mesenchymal Stem Cell Research: Studies on MSC chondrogenic differentiation and cartilage formation
• Bioreactor Culture Systems: Examination of mechanical stimulation effects on engineered cartilage
• Tissue Maturation Research: Investigation of engineered cartilage matrix organization and mechanical properties

Experimental models include hydrogel encapsulation, electrospun scaffolds, 3D bioprinting, and perfusion bioreactor systems.

Laboratory Handling and Storage Protocols

Lyophilized Powder Storage:

• Store at 2-8°C (refrigerated) in original sealed vial
• Protect from light exposure and moisture
• Do not freeze lyophilized powder
• Stable for 24 months refrigerated as unopened vial
• Record receipt date for laboratory inventory

Handling Precautions:
Bioregulator peptide preparations require careful handling to maintain activity:

• Use sterile technique for cell culture applications
• Avoid prolonged exposure to room temperature
• Minimize exposure to direct light
• Use appropriate peptide-compatible labware (low-binding tubes)
• Follow standard laboratory peptide handling protocols

Quality Assurance and Analytical Testing

Each Cartalax batch undergoes characterization appropriate for a defined synthetic peptide:

Identity and Sequence Analysis:

• High-Performance Liquid Chromatography (HPLC): Purity ≥98%
• Molecular weight confirmation: ESI-MS verifies the expected mass of 333.29 Da
• Amino acid analysis: Confirms the Ala-Glu-Asp (AED) composition
• Peptide content determination: Quantifies actual peptide content by weight

Purity Testing:

• Protein purity: Bradford or BCA assay for total protein content
• Related substances: Verification of low synthesis-related impurity content
• Non-peptide components: Carbohydrate and lipid content below specified limits
• Heavy metals: Below detection limits per pharmacopeia standards

Contaminant Testing:

• Bacterial endotoxin: <10 EU/mg (LAL method)
• Sterility testing: Sterile filtration and microbiological testing
• Residual solvents: Within acceptable limits
• Water content: Karl Fischer titration (<8%)

Synthesis and Consistency Verification:

• Origin: Chemically synthesized by solid-phase peptide synthesis
• Sequence confirmation: Identity verified as Ala-Glu-Asp (AED)
• Processing validation: Standardized synthesis and purification protocols
• Batch-to-batch consistency: Quality control testing across production batches

Documentation:

• Certificate of Analysis (COA) with batch-specific data
• HPLC purity chromatogram
• Quality control test results
• Storage and handling recommendations
• Lot number traceability

Research Considerations

Experimental Design Factors:

Researchers should consider several factors when designing experiments with Cartalax:

1. Concentration Selection: Bioregulator peptide research typically employs concentrations ranging from 0.1-10 μg/mL in cell culture studies. Optimal concentration should be determined empirically for specific experimental systems.

2. Treatment Duration: Published research suggests effects may require 24-72 hours to manifest in cell culture models. Longer durations (5-14 days) often used for matrix synthesis studies.

3. Cell Type Specificity: While designated as cartilage-specific, tissue selectivity should be verified in each experimental system through comparative studies with other cell types.

4. 3D Culture Considerations: Chondrocytes in 3D culture better maintain phenotype. Consider alginate beads, agarose, or hydrogel encapsulation for physiologically relevant studies.

5. Defined Sequence Considerations: As a single defined tripeptide, observed effects can be attributed to a known molecular entity, supporting reproducible mechanism studies.

Control Groups:

Appropriate controls for bioregulator peptide research include:

• Vehicle control (vehicle buffer only)
• Non-specific peptide control (scrambled peptides or unrelated bioregulator)
• Positive controls where applicable (TGF-β, IGF-1 for anabolic effects)
• Tissue-specific comparisons (same bioregulator concentration in non-cartilage cells)

Mechanism Investigation:

Cartalax mechanisms remain active research areas. Investigated mechanisms include:

• Gene expression modulation through transcription factor regulation (SOX9, RUNX2)
• Epigenetic modifications influencing chondrocyte gene expression
• Growth factor receptor signaling (TGF-β, IGF-1 pathways)
• Intracellular signaling pathway activation (MAPK, Smad, PI3K/Akt)
• MMP/TIMP balance regulation
• Direct nuclear effects on chromatin and gene regulation

Research approaches combine molecular biology techniques, genomic and proteomic analysis, biochemical matrix assays, and functional tissue assessments to elucidate bioregulator action mechanisms.

Compliance and Safety Information

Regulatory Status:
Cartalax is provided as a research chemical for in-vitro laboratory studies and preclinical research only. This bioregulator peptide has not been approved by the FDA for human therapeutic use, dietary supplementation, or medical applications.

Intended Use:

• In-vitro cell culture research
• Cartilage explant studies
• In-vivo preclinical research in approved animal models
• Laboratory investigation of cartilage tissue regulation
• Academic and institutional research applications

NOT Intended For:

• Human consumption or administration
• Therapeutic treatment or diagnosis
• Dietary supplementation
• Veterinary therapeutic applications without appropriate oversight
• Any medical or clinical applications

Safety Protocols:
Researchers should follow standard laboratory safety practices:

• Use appropriate personal protective equipment (lab coat, gloves, safety glasses)
• Handle in biosafety cabinet for sterile work
• Follow institutional biosafety guidelines
• Dispose of waste according to laboratory waste protocols
• Consult material safety data sheet (MSDS) for additional information

Handling Notes:
Cartalax is a chemically synthesized peptide of non-animal origin. Researchers should:

• Follow institutional synthetic peptide handling guidelines
• Maintain records of certificate of analysis documentation
• Apply appropriate biosafety level for in-vitro reagents
• Store and label material per institutional chemical inventory policy

—